Skip to main content
OpenTrials
Completed

NCT Number: NCT02445521

Testing of Four Home Phenylalanine Monitoring Prototype Devices

The objective of this study is to test four home phenylalanine monitoring prototype devices, selected out of a pool of candidates by the National PKU Alliance Scientific Committee.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Children's Healthcare of Atlanta (CHOA), Atlanta, Georgia, United States

Loading trial locations.

About this study

A real time, point-of-care and home phenylalanine monitoring system would provide patients with quick results and feedback. Home monitoring devices' phenylalanine measurements will be compared to the current gold-standard measurement of phenylalanine (plasma concentration) in four subjects with PKU and one control subject. The study will enroll subjects with different baseline phenylalanine concentrations (i.e., patients with poor to good metabolic control, assessed by comparing current phenylalanine concentrations to established treatment ranges).

For each prototype device, three separate measurements of phenylalanine per subject will be performed. Three prototype devices require whole blood, thus 1 teaspoon (approximately 4mL) of whole blood will be collected through venipuncture and blood spots will be used to conduct tests. One prototype requires capillary blood to be collected through a fingerstick, and will require three blood spots from the stick. A single plasma amino acid analysis for each participant will also be performed using leftover whole blood from the 4mL blood draw through quantitative ion exchange chromatography, reported as micromoles/L.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosis of PKU or hyperphenylalaninemia (PKU group)
  • any age
  • in good health (PKU and control group)

Exclusion criteria

  • pregnant
  • have any medical comorbidities
  • considered unfit for participation by the principal investigator

Treatment and study plan

Primary outcomes

  1. Intra-variability of the four devices, assessed by phenylalanine values

    Time frame: Day 1

    Phenylalanine values for each of the three runs on each device for the same individual will be compared. Each PKU subject will be assessed separately to assess the reliability of each device since the subjects will have a range of phenylalanine concentrations.

Secondary outcomes

  1. Inter-variability of the four devices, assessed by average phenylalanine concentrations

    Time frame: Day 1

    Average phenylalanine values measured by the four tests of each device in each subject will be calculated. Mean concentrations for each device will be compared to the control (gold standard measure of plasma phenylalanine).

Sponsors and collaborators

Lead sponsor

Emory University

Other

Collaborators

  • National PKU Alliance

Registry information

Official study title

Testing of Four Home Phenylalanine Monitoring Prototype Devices Using Whole Blood From Normal and PKU Subjects

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
May 15, 2015
Registry last updated
Dec 11, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.